



ISPOR 5TH LATIN AMERICA CONFERENCE

ISPOR Santiago



6-8 September 2015
CentroParque Event & Convention Center
located in Parque Araucano
Santiago, Chile

*Increasing Access to Health Care in Latin America:
Making Better Decisions for Greater Equity*

Early Registration
Deadline:
21 July 2015

CONFERENCE FEATURES
OVER 450 PRESENTATIONS!



PROGRAM

CO-ORGANIZED BY: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
ISPOR Latin America Consortium & ISPOR Chile Regional Chapter

Supporting Institutions (as of May 2015)

- Institute for Health Technology Assessment (IETS), Colombia
- General Health Counsel (CSG), Ministry of Health, México
- General Coordination for HTA, Department of Science and Technology, Ministry of Health (DECIT-CGATS), Brazil
- Institute for Clinical Effectiveness and Health Policy (IECS), Argentina
- SaluDerecho (a World Bank initiative on prioritization, equity, and constitutional mandates in health), Washington, DC
- Interdepartmental Center for Health Economics (GRIDES), Federal University of São Paulo, Brazil
- Division of Health Technology Assessment (gETS), Ministry of Public Health, Uruguay
- National Board of Health of the Armed Forces (D.N.S.F.F.AA.), Uruguay

Conference Program Committee

PROGRAM COMMITTEE CO-CHAIRS

Jeanette Vega Morales, MD, MPH, PhD, Director, National Health Fund of Chile (FONASA), Santiago, Chile

Rony Lenz Alcayaga, MA, Professor, School of Public Health, University of Chile and Head Consultant, Lenz Consulting, Santiago, Chile

ISSUE PANEL REVIEW COMMITTEE CO-CHAIRS

Manuel Antonio Espinoza, MD, MSc, PhD, Professor, Department of Public Health & Coordinator, Unit of Health Technology Assessment, Center for Clinical Investigation, Catholic University of Chile, and Scientific Advisor, Department of Scientific Affairs, Public Health Institute of Chile, Santiago, Chile

Mario Giorgio Saggia, MBA, Managing Partner, ASIGMA, São Paulo, Brazil

WORKSHOP REVIEW COMMITTEE CO-CHAIRS

Alarico Rodriguez, MD, Medical Benefits Manager, Uruguayan National Agency for Highly Specialized Medical Procedures, Montevideo, Uruguay

Rosa María Galindo-Suárez, MHE, Prioritization Deputy Director, General Health Council, Ministry of Health, México, D.F., Mexico

RESEARCH REVIEW COMMITTEE CO-CHAIRS

Federico Augustovski, MD, MSc, PhD, Director, Economic Evaluations and HTA Department, Institute for Clinical Effectiveness and Health Policy (IECS) and Professor of Public Health, University of Buenos Aires, Buenos Aires, Argentina

Diego Rosselli, MD, MEd, MHP, Associate Professor, Health Economics, Javeriana Papal University, Bogotá, Colombia

Venue Information/Hotel Reservations

CENTROPARQUE EVENT & CONVENTION CENTER

Presidente Riesco 5330 Nivel/Level A-B, Parque Araucano, Las Condes, Santiago, Chile
The conference will be held at the beautiful CentroParque Convention Center, which is located in the heart of Santiago's Araucano park. This venue will accommodate ISPOR's growing regional engagement in the field of health economics and outcomes research in a modern and convenient conference space. CentroParque Event & Convention Center is located approximately 20 km (12 miles) from Aeropuerto Internacional Arturo Merino Benítez (SCL), the main airport serving Santiago, Chile.

HOTEL RESERVATIONS

ISPOR has arranged delegate rates at the **Grand Hyatt Santiago**. The Grand Hyatt Santiago is approximately a 5-10 minute walk from CentroParque Event & Convention Center.

ISPOR Rates: The discounted room rate for ISPOR conference attendees is 115,000 CLP (\$189 USD) Single Occupancy / 128,500 CLP (\$211 USD) Double Occupancy, plus applicable taxes.

Reservations: Use the online booking link available at www.ispor.org >> 5th Latin America Conference >> Attendee Information >> Hotel and Venue Information.

Research Poster Presentations

POSTER PRESENTATIONS SESSION I: MONDAY, 7 SEPTEMBER

Display Hours: 8:30-20:00 • Poster Author Discussion Hour: 18:30-19:30

POSTER PRESENTATIONS SESSION II: TUESDAY, 8 SEPTEMBER

Display Hours: 8:30-15:00 • Poster Author Discussion Hour: 12:00-13:00

For More Info: www.ispor.org



Tweet about this conference to
[@ISPORorg](https://twitter.com/ISPORorg) using #ISPORSantiago



ISPOR 5TH LATIN AMERICA CONFERENCE

6-8 September 2015, Santiago, Chile

Short Course Program

Sunday, 6 September

Complete Short Course descriptions available at www.ispor.org

All Day Short Courses (8:00-17:00)

INTRODUCTION TO HEALTH ECONOMICS (Presented in Spanish)

Track: Economic Methods

Level: **Introductory.** This course is suitable for those with little or no experience with pharmacoeconomics.

Faculty: **Diego Rosselli, MD, MEd, MHP**, Associate Professor, Health Economics, Pontificia Universidad Javeriana, Bogotá, Colombia; **Manuel A. Espinoza, MD, MSc, PhD**, Professor, Department of Public Health & Coordinator, Unit of Health Technologies Evaluation, Center for Clinical Research, Catholic University of Chile and Scientific Advisor, Department of Scientific Affairs, Public Health Institute of Chile, Ministry of Health, Santiago, Chile

Course Description: Designed to teach clinicians and new researchers how to incorporate pharmacoeconomics/health economics into study design and data analysis. Participants of this course will learn how to collect and calculate the costs of different health care or health care economic evaluation alternative treatments, determine the economic impact of clinical outcomes, and how to identify, track, and assign costs to different types of health care resources used. The development of economic protocols and data collection sheets will be discussed. Different health economics models and techniques will be demonstrated with case studies. These include: cost-minimization, cost-of-illness, cost-effectiveness, cost-benefit, and cost-utility analysis. Decision analysis, sensitivity analysis, and discounting will also be demonstrated and practiced. Participants will learn to compare and evaluate interventions such as drugs, devices, and clinical services.

APPLIED MODELING (Presented in English, Portuguese, and Spanish with simultaneous interpretation provided)

Track: Modeling Methods

Level: **Advanced.**

Prerequisite: This course is suitable for those who are familiar with modeling methods and/or those who have previously taken the ISPOR Short Course, "Introduction to Modeling."

Faculty: **Mark Sculpher, PhD, MSc**, Professor of Health Economics, Centre for Health Economics, University of York, Heslington York, UK; **Andrew Briggs, DPhil, MSc**, William R Lindsay Chair of Health Economics, Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK; **Pedro Saramago Goncalves, PhD, MSc**, Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK; **Marta Soares, MSc**, Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK

Course Description: This course is a hands-on introduction to the use of software in the creation and analysis of cost-effectiveness decision models. The basics of cost-effectiveness decision making, building, and analyzing a simple decision tree will be discussed. Markov modeling and Monte Carlo simulation will be introduced.

All participants must bring a Windows laptop computer with a copy of TreeAge Pro Suite installed and running. You will be provided download and installation instructions when you pre-register for the course.

Morning Short Courses (8:00-12:00)

INTRODUCTION TO MODELING (Presented in Spanish)

Track: Modeling Methods

Level: **Introductory.** This introductory course requires a basic familiarity with decision analysis.

Faculty: **Federico Augustovski, MD, MSc, PhD**, Director, Economic Evaluations and HTA Department, Institute for Clinical Effectiveness and Health Policy (IECS), Professor of Public Health, University of Buenos Aires, Buenos Aires, Argentina

Course Description: This course includes a review of Markov models, discrete event models, and other modeling techniques and their appropriate applications, including a review of the *ISPOR Principles of Good Practice for Decision Analytic Modeling in Health Care Evaluations*, as well as the recent ISPOR-SMDM guidelines (*Value in Health* 2012). Using a series of related examples, the course will carefully review the practical steps involved in developing and using these kinds of models. Instructors will cover the practical steps involved in the selection and modeling of data inputs and practical aspects related to the determination of when, why, and how to handle stochastic (i.e., first order Monte Carlo Simulations) and probabilistic uncertainty (i.e., second order Monte Carlo Simulations). Issues related to the selection of model input parameters and their distributions for use in probabilistic sensitivity analyses will be considered.

HEALTH-RELATED QUALITY OF LIFE / UTILITY MEASURES (Presented in Spanish)

Track: Patient-Reported Outcomes/Preference Methods

Level: **Introductory/Intermediate.** This course is for those with some experience with quality of life measures in health economic evaluation.

Faculty: **Rafael Alfonso, MD, MSc, PhD**, Director, Value Evidence Analytics, GlaxoSmithKline R&D, King of Prussia, PA and Affiliate Professor, Department of Surgery, University of Washington, Seattle, WA, USA; **Yajaira Bastardo, PhD**, Professor & Chair of Pharmacoeconomics & Pharmacy Administration, Central University of Venezuela, School of Pharmacy, Caracas, Venezuela

Course Description: Conceptual, methodological, and practical methods for measuring quality of life, health status and other types of health outcomes will be presented. Utility measurement, a method of determining an individual's preference for a certain outcome represented by a quantitative score (utility), will also be reviewed. Methods for measuring preference-based outcomes like the standard gamble, time trade-off, and visual analogue scale will be demonstrated. Additionally, utility-based instruments such as the EQ-5D, HUI, QWQ

and SF-36 will be briefly discussed. Utility measurement, however, is not only about mastering these techniques; it is about using them in such a way that health care decision makers can apply the results, for instance, in cost per QALY analyses. For this purpose, one needs to be aware of shortcomings of the available utility measures and potential solutions. Furthermore, one should be aware of the decision-making context and the way results are interpreted. To equip participants with expertise in the field of utility measurement, the most important issues will be discussed, such as potential insensitivity of generic instruments for particular disease-specific problems, and to what extent adaptation of generic or disease-specific quality of life instruments may offer a solution. Also, the issue of "whose values count: patient values or values from the general public?" will be discussed. Finally, we turn to the interpretation in the context of resource allocation.

Afternoon Short Courses (13:00-17:00)

EXTRACTING COST DATA FOR ECONOMIC ANALYSIS IN LATIN AMERICA (Presented in Spanish)

Track: Economic Methods

Level: **Intermediate.** This course is designed for those with some experience with pharmacoeconomic analysis.

Faculty: **Ximena Burbano-Levy, MD, MPH**, Founder & CEO, Zilonis Health Economics Consulting Group, Miami, FL, USA

Course Description: This course will focus on practical aspects of cost development for pharmacoeconomic studies. The objective is to help the participant bridge the gap between understanding pharmacoeconomic theory and the practice of developing cost estimates. Factors to consider when costing pharmacoeconomic analyses such as perspective, data sources, data classification systems, developing resource use profiles, obtaining unit costs, and making cost adjustments will be presented. Examples of issues encountered when identifying and extracting cost data will be discussed.

META-ANALYSIS & SYSTEMATIC LITERATURE REVIEW (Presented in Spanish)

Track: Outcomes Research Methods

Level: **Intermediate.** This course is designed for those with some experience with pharmacoeconomic analysis/outcomes research methods.

Faculty: **Agustin Ciapponi, MD**, Coordinator, Argentine Cochrane Centre-IECS (Institute for Clinical Effectiveness and Health Policy), Buenos Aires, Argentina; **Gabriel Rada, MD**, Unit of Evidence-based Medicine, Catholic University of Chile, Department of Family Medicine, Santiago, Chile

Course Description: Faculty will discuss systematic literature review and meta-analytic methods used to assess the quality of evidence for health care interventions. Statistical approaches to pooling results from several studies and application of meta-analysis in pharmacoeconomic studies and health care decision making will be presented.



ISPOR 5TH LATIN AMERICA CONFERENCE

6-8 September 2015, Santiago, Chile

Over 800
attendees
expected!

Conference Program

Sunday, 6 September

8:00-17:00

Pre-Conference Short Courses

17:15-18:15

Educational Symposium

HOW IS ADVANCED GASTRIC CANCER TREATED IN LATIN AMERICA? HOW CAN WE REDUCE THE BURDEN OF THE DISEASE?

Currently available medical strategies for the management of gastric cancer are extremely limited. While innovative therapies for managing this disease are now available, these therapies also have a higher acquisition cost and have implications for how a payer will deal with integrating these therapies given the constraint on their drug budget, as well as how these agents are assessed (HTA) by governments and how they decide on the appropriate use. The cost of gastric cancer, role of these new agents, and their potential impact on patients and the health care system will be discussed. *(Sponsored by Eli Lilly)*

18:30-19:30

Educational Symposium

SUSTAINABLE UNIVERSAL HEALTH COVERAGE

Achieving the goals of universal health coverage requires a structured, collaborative effort that ensures health systems use resources effectively and efficiently. This symposium will explore broader approaches to health technology assessment and formulary development in middle-income countries. *(Sponsored by PhRMA)*

19:45-20:45

Educational Symposium

CHALLENGES AND OPPORTUNITIES FOR OBSERVATIONAL RESEARCH IN REAL WORLD SETTINGS

This symposium will highlight the importance of observational studies in patient outcomes by presenting the learnings of a series of observational studies in Latin America. *(Sponsored by Amgen)*

21:00-22:30

Welcome Reception

Monday, 7 September

8:30-20:00

Research Poster Presentations Viewing – Session I

8:30-9:00

Welcome Address & Opening Remarks

9:00-10:30

First Plenary Session

IS HTA FAIR? ANALYZING THE HTA PROCESS IN LATIN AMERICA & ITS IMPLICATIONS FOR ACCESS TO HEALTH CARE

Health technology assessment (HTA) is increasingly being used by public and private payers in Latin America to assess the effectiveness and efficiency of health care technologies for their populations – but is it fair? HTA has been implemented as a way to enable better decisions that balance varied societal and stakeholder perspectives and needs, but there still persists the question of whether or not the decisions being made fairly represent all stakeholders. Panelists will discuss these issues from a perspective of working in the environment of fairness, while balancing the requirements of a rigorous scientific method to evaluate the usefulness of drugs and devices for their populations.

10:30-11:00

Break, Exhibits & Research Poster Presentations Viewing – Session I

11:00-12:00

Issue Panels – Session I

IP1: DIFFICULTIES IN ESTABLISHING THE WILLINGNESS-TO-PAY THRESHOLD IN LATIN AMERICAN COUNTRIES – WHAT ARE THE POSSIBLE PATHWAYS?

Moderator: Rodrigo Antonini Ribeiro, MD, MSc, PhD, Institute for Education and Research, Hospital Moinhos de Vento, Porto Alegre, Brazil

Panelists: Federico Augustovski, MD, MSc, PhD, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina; Tomas A. Pippo Briant, MSc, Ministry of Health of Argentina, Buenos Aires, Argentina; Vanía Cristina Canuto Santos, MSc, Ministry of Health of Brazil, Brasília, Brazil

IP2: DISINVESTMENT IN LATIN AMERICA: WHAT ARE THE EXPERIENCES, CHALLENGES, AND PROPOSALS FOR ITS SUCCESSFUL IMPLEMENTATION?

Moderator: Ion Agirrezabal, MSc, Costello Medical Consulting Ltd., Cambridge, UK

Panelists: Alarico Rodríguez, PhD, Fondo Nacional de Recursos, Montevideo, Uruguay; María Eugenia Esandi, PhD, Universidad Nacional del Sur, Buenos Aires, Argentina; Iñaki Gutiérrez-Ibarluzea, PhD, Basque Office for HTA, Vitoria-Gasteiz, Spain

IP3: PLANES DE BENEFICIOS EN SALUD EN LATINOAMÉRICA: ¿CUÁL ES EL ESTADO ACTUAL Y CUÁLES SON LOS DESAFÍOS FUTUROS?

Moderator: Manuel A. Espinoza, MD, MSc, PhD, Pontificia Universidad Católica de Chile, Santiago, Chile

Panelists: Ursula Giedion, MSc, MA, Banco Interamericano de Desarrollo, Bogotá, Colombia; Andrés Pichon-Riviere, MD, MSc, PhD, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina

IP4: CAN WE STRENGTHEN RESEARCH CAPACITY OF HEALTH TECHNOLOGY ASSESSMENT WITHIN LATIN AMERICA?

Moderator: Virginia Becerra, MSc, PhD, AbbVie, Montevideo, Uruguay

Panelists: Rosina Hinojosa, MSc, Pfizer Peru, Lima, Peru; Jose Luis Segú, MSc, Oblikue Consulting, Barcelona, Spain; Rony Lenz, MA, Universidad de Chile, Santiago, Chile

IP5: COOPERAÇÃO INTERNACIONAL ENTRE ARGENTINA, BRASIL E URUGUAI: COMO É QUE A PRODUÇÃO DE ESTUDOS DE CUSTO-EFETIVIDADE E INTERCÂMBIO DE CONHECIMENTO EM SAÚDE NO ÂMBITO DO MERCOSUL DA SUPORTE A TOMADA DE DECISÃO?

Moderator: Telma Rodrigues Caldeira, Especialista em vigilância sanitária, Agência Nacional de Vigilância Sanitária - Anvisa, Brasília, Brazil

Panelists: Roberta Wichmann, MSc, PhD, Ministério da Saúde do Brasil, Brasília, Brazil; Analia del Carmen Amarilla, MD, Ministerio de Salud Argentina, Buenos Aires, Argentina; Alejandra Nelly Croci González, BA, Ministry of Health of Uruguay, Montevideo, Uruguay

12:00-15:00

Lunch, Exhibits & Research Poster Presentations Viewing – Session I

12:30-13:30

Educational Symposium

NEW MODELS TO EXPAND REAL-WORLD EVIDENCE (RWE) OPPORTUNITIES IN LATIN AMERICA THROUGH COLLABORATIONS

Novel approaches to build real-world evidence (RWE) in Latin America will be discussed and illustrated by case examples of collaborative work to develop real-world data (RWD) sources including clinical and claims information with payers, providers, and electronic medical record (EMR) systems in Mexico and Brazil, as a model to develop RWD in other Latin American markets. *(Sponsored by IMS Health)*

Session titles are listed in this Program as originally submitted by the Presenter(s) and are subject to change. Confirmed session languages will be available at the ISPOR website – www.ispor.org.



ISPOR 5TH LATIN AMERICA CONFERENCE

6-8 September 2015, Santiago, Chile

Conference Program continued

13:45-14:45

Educational Symposium

USING DATA AND ANALYTICS TO OPTIMIZE CARE, BENEFITS, AND AFFORDABILITY

This symposium presents a case study about innovative medical protocols that have been successfully embedded into Amil clinics and emergency room electronic medical records (EMRs). The panel will detail these protocols, their function as evidence-based tools for promoting quality of care and cost management, and how they can prove advantageous for both patients and payers. (Sponsored by Optum)

15:00-16:00

Workshops & ISPOR Forum – Session I

W1: CHANGING THE HISTORY OF COST-EFFECTIVENESS DECISION RULES: HOW THE FIRST EMPIRICAL ESTIMATES OF COST-EFFECTIVENESS THRESHOLD WILL IMPACT THE DECISION PROCESSES IN LATIN AMERICA?

Discussion Leaders: Manuel A. Espinoza, MD, MSc, PhD, Pontificia Universidad Católica de Chile, Santiago, Chile; Marta Soares, MSc, University of York, Heslington, York, UK; Mark J. Sculpher, MSc, PhD, University of York, Heslington, York, UK

W2: HTA: UNDERSTANDING THE IMPACT ON PATIENT ACCESS AND INTERNATIONAL REFERENCE PRICING IN LATIN AMERICA

Discussion Leaders: Diego Guarín, MD, MPH, MA, Merck Sharp & Dohme, Bogotá, Colombia; Mónica Martín de Bustamante, AB, BE, CBPartners, New York, NY, USA; Rafael Alfonso, MD, PhD, GSK, King of Prussia, PA, USA; J. Jaime Caro, MDCM, FRCPC, FACP, Evidera, Lexington, MA, USA

W3: GENERATING AND USING REAL-WORLD EVIDENCE IN LATIN AMERICA: SETTING PARTNERSHIPS, FINDING DATA, ASSESSING APPROPRIATELY, AND MAKING DECISIONS: LOCAL, INTERNATIONAL, PUBLIC, AND PRIVATE PERSPECTIVES

Discussion Leaders: Nahila Justo, MPhil, MSc, MBA, MAPI Group, Stockholm, Sweden; Joaquin Mould Quevedo, PhD, MSc, MBA, Bayer Healthcare, Berlin, Germany; Gerardo Machnicki, MSc, PhD, Janssen LATAM, Buenos Aires, Argentina; Iris Contreras-Hernandez, MD, MSc, Instituto Mexicano del Seguro Social, México, D.F., Mexico

W4: INDIRECT TREATMENT COMPARISONS: GUIDANCE ON TECHNICAL ASPECTS OF CONDUCTING AND INTERPRETING NETWORK META-ANALYSES

Discussion Leaders: Agustín Ciapponi, MD, MSc, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina; David Thompson, PhD, Quintiles, Cambridge, MA, USA

W5: A METHOD FOR THE ELICITATION OF IMPRECISE CRITERIA WEIGHTS IN MULTI-CRITERIA DECISION ANALYSIS FOR HEALTH CARE

Discussion Leaders: Vakaramoko Diaby, PhD, Florida A&M University, Tallahassee, FL, USA; Vassiki Sanogo, PhD, Florida State University, Tallahassee, FL, USA

F1: PROCESOS DE PARTICIPACIÓN PARA ACTUALIZACIÓN DE PLANES DE BENEFICIOS

Presented by the ISPOR Colombia Chapter

Moderator: TBD

Speakers: Diana Esperanza Rivera Rodríguez, MSc, EGP, Instituto de Evaluación Tecnológica en Salud (IETS), Bogotá, Colombia; Diego Rosselli, MD, EdM, MSc, Pontificia Universidad Javeriana, Facultad de Medicina, Bogotá, Colombia

16:00-16:15

Break, Exhibits & Research Poster Presentations Viewing – Session I

Session titles are listed in this Program as originally submitted by the Presenter(s) and are subject to change. Confirmed session languages will be available at the ISPOR website – www.ispor.org.

16:15-17:15

Research Podiums – Session I

CANCER OUTCOMES RESEARCH STUDIES

CA1: ASOCIACIÓN SIGNIFICATIVA ENTRE LA ENFERMEDAD VOLUMINOSA CERCANA A CRANEO Y NEUROEJE Y LA INFILTRACIÓN SECUNDARIA A SISTEMA NERVIOSO CENTRAL EN PACIENTES CON LINFOMA DIFUSO DE CÉLULAS GRANDES B

Huerta-Guzman J¹, Ignacio-Ibarra G¹, Talavera-Piña J¹, Sierra-Ramírez J², Contreras Hernández I¹, ¹Instituto Mexicano del Seguro Social, Mexico, D.F., Mexico, ²Instituto Politécnico Nacional, México, D.F., Mexico

CA2: ACCESS TO THE PROCEDURE CARE OF COLORECTAL CANCER IN BRAZILIAN PUBLIC HEALTH SYSTEM: USE OF DIAGNOSIS RESOURCES IN SÃO PAULO STATE

Oliveira D¹, Luque A¹, Junqueira Junior SM¹, Oliveira FMP¹, Cabra HA², ¹Johnson & Johnson Medical Brazil, São Paulo, Brazil, ²Johnson & Johnson Medical, Mexico, D.F., Mexico

CA3: PROFILE OF COLORECTAL CANCER TREATMENT WITHIN BRAZILIAN PUBLIC SETTING: ANALYSIS OF DATASUS AQ DATABASE

Fabre Ballalai Ferraz A¹, Rosim R¹, Anaya P², ¹IMS Health, São Paulo, Brazil, ²IMS Health, México, D.F., Mexico

CA4: COSTO DE CÁNCER DE COLON AVANZADO EN LOS ESTABLECIMIENTOS HOSPITALARIOS DEL PERÚ

Gutierrez-Aguado A¹, Escobedo-Palza S², Timana-Ruiz R³, Sobrevilla-Ricci A⁴, Mosqueira-Lovón R⁴, ¹UNMSM, Lima, Peru, ²SPEAS, Lima, Peru, ³SOMPEGS, Lima, Peru, ⁴Abt Associates-HFG Peru, Lima, Peru

COST-EFFECTIVENESS STUDIES

CE1: COST-EFFECTIVENESS ANALYSIS FOR CERVICAL CANCER SCREENING USING HPV TESTS IN CHILE

Franco Figueira S¹, Cachoeira CV¹, Souza FH¹, Kano BY¹, Silva M², ¹Roche Diagnostics LATAM, São Paulo, Brazil, ²Roche Diagnostics Chile, Santiago, Chile

CE2: EVALUACIÓN DEL COSTO-EFECTIVIDAD Y COSTO-UTILIDAD DEL USO DE RIVAROXABÁN EN PACIENTES CON FIBRILACIÓN AURICULAR NO VALVULAR FRENTE A WARFARINA EN EL CONTEXTO ECUATORIANO

Romero M, Alfonso Quiñones PA, Acero G, Marrugo R, Salutia Foundation, Bogotá, Colombia

CE3: PROJECTED ECONOMIC IMPACT OF INCREASED USE OF BIOLOGIC TREATMENTS FOR RHEUMATOID ARTHRITIS IN ARGENTINA, COLOMBIA, AND MEXICO OVER 10 YEARS

Rojas Serrano J¹, de Abreu MM², Tundia N³, Skup M³, Sorg R⁴, Macaulay D⁴, Bao Y³, Chaves L³, Chao J³, ¹National Autonomous University of Mexico, México, D.F., Mexico, ²Federal University of Rio de Janeiro, Rio de Janeiro, Brazil, ³AbbVie Inc., North Chicago, IL, USA, ⁴Analysis Group, Inc., New York, NY, USA

CE4: EVALUACIÓN COSTO-UTILIDAD DE DOS ALTERNATIVAS DE VACUNACIÓN PARA EL VIRUS DEL PAPILOMA HUMANO (VPH) EN LA PREVENCIÓN DEL CÁNCER CERVICAL UTERINO

Tejada RA, Bolaños-Díaz R, Beltrán J, Roman Y, Instituto Nacional de Salud, Lima, Peru

INFECTIOUS DISEASE STUDIES

IN1: ANÁLISIS DE COSTO UTILIDAD DE PCV13 VERSUS PPSV23 EN ADULTOS DE 65 AÑOS Y MÁS


Biagini Leandro L¹, Rojas Ruben R¹, Fuentealba Francisca F¹, Pezzani Marcela M², ¹Universidad Mayor, Santiago, Chile, ²Universidad San Sebastián, Santiago, Chile

IN2: METHODOLOGICAL CHANGES IN BURDEN OF INFECTIOUS DISEASE ESTIMATION: THE CASE OF PNEUMOCOCCAL INFECTION IN COLOMBIA

Lasalvia P¹, Castañeda-Cardona C¹, Rosselli D², ¹Pontificia Universidad Javeriana, Bogotá, Colombia, ²Pontificia Universidad Javeriana, Facultad de Medicina, Bogotá, Colombia

IN3: ESTIMATING THE SUPPLY AND DEMAND OF BUTANTAN DENGUE VACCINE IN BRAZIL

García CR¹, Wilson-Barthes M¹, Coelho GE², Domingues C², Constenla DO¹, ¹Johns Hopkins University, Baltimore, MD, USA, ²Ministério da Saúde, Brasília, Brazil



ISPOR 5TH LATIN AMERICA CONFERENCE

6-8 September 2015, Santiago, Chile

Conference Program continued

IN4: ECONOMIC COSTS OF BACTERIAL MENINGITIS: A SYSTEMATIC REVIEW

Alvis-Zakzuk N¹, Carrasquilla-Sotomayor M², **Alvis-Guzman N²**, Paternina-Caicedo A², Herrera-Arrieta J³, Coronel-Rodriguez W², Castillo-Saavedra D⁴, ¹Instituto Nacional de Salud, Bogotá, Colombia, ²Universidad de Cartagena, Centro de Investigación y Docencia, Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, ³Universidad del Sinu, Cartagena, Colombia, ⁴Funiderma, Grupo de Investigación en Economía de la Salud, Bogotá, Colombia

MEDICAL DEVICE & DIAGNOSTIC RESEARCH STUDIES

MD1: EVALUACIÓN ECONÓMICA DEL CARDIO-DESFIBRILADOR IMPLANTABLE COMPARADO CON LA TERAPIA FARMACOLÓGICA ÓPTIMA PARA EL TRATAMIENTO DE LOS PACIENTES CON FALLA CARDIACA EN COLOMBIA

Atehortua SC¹, Castro P¹, Ceballos M², Senior JM¹, Saldarriaga C¹, Giraldo N¹, ¹Universidad de Antioquia, Medellín, Colombia, ²Instituto de Evaluación Tecnológica en Salud (IETS), Bogotá, Colombia

MD2: MEDICAL DEVICES – FROM LICENSING TO COVERAGE: HIGHLIGHTS FROM ARGENTINA, BRAZIL, COLOMBIA, AND MEXICO

Rey-Ares L¹, Garay U¹, García Martí S¹, Gilardino R², Cabra HA³, Pichón-Riviere A¹, Augustovski F¹, ¹Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, ²Johnson & Johnson Medical Argentina, Buenos Aires, Argentina, ³Johnson & Johnson Medical, México, D.F., Mexico

MD3: STAPLED HAEMORRHOIDOPEXY TO TREAT HEMORRHOIDS GRADE III AND IV: A SYSTEMATIC REVIEW AND META-ANALYSIS

Luque A¹, Junqueira Junior SM¹, Oliveira FMP¹, Oliveira D¹, Cabra HA², ¹Johnson & Johnson Medical Brazil, São Paulo, Brazil, ²Johnson & Johnson Medical, México, D.F., Mexico

MD4: COST EFFECTIVENESS OF DRUG COATED BALLOON VERSUS PERCUTANEOUS TRANSLUMINAL BALLOON ANGIOPLASTY IN THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE IN LOWER LIMBS IN BRAZIL

Pepe C¹, Fahham L², Follador W³, Valencia J⁴, **Orozco JJ⁵**, ¹Grupo Resulta, São Paulo, Brazil, ²Sense Company, São Paulo, Brazil, ³Medtronic, São Paulo, Brazil, ⁴Medtronic, Miami, FL, USA, ⁵Medtronic, Medellín, Colombia

PRICING AND HEALTH SYSTEM STUDIES

PR1: TIERED-PRICING STRATEGIES: THE WAY FORWARD FOR DRUG ACCESS IN LATIN AMERICA?

Senan B, Vidal-Pinheiro A, Sandorff E, ICON, London, UK

PR2: COMPETITION AND STRATEGIC REGULATION IN THE ARGENTINE PHARMACEUTICAL MARKET: A COMPARATIVE STUDY OF SIX THERAPEUTIC CLASSES

Maceira D, Palacios A, Center for the Study of State and Society (CEDES), Buenos Aires, Argentina

PR3: POTENTIAL PUBLIC RESOURCE SAVINGS IN BRAZIL: THE SOMATROPIN CASE

Lemos LLP¹, Silva MRR¹, Santos JB², Costa JDO¹, Gomes RM¹, Nascimento RC², Almeida AM³, Guerra Júnior AA², ¹CCATES, Federal University of Minas Gerais, Belo Horizonte, Brazil, ²College of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil, ³College of Medical Sciences of Minas Gerais, Belo Horizonte, Brazil

PR4: IMPACT OF MAJOR CHANGES TO THE BRAZILIAN HEALTH CARE SYSTEM UTILIZING THE HEAT MAPS PROJECT

Panish JM¹, Junqueira Junior SM², Cabra HA³, Hutzul T⁴, Hensen M⁵, ¹Ethicon, Somerville, NJ, USA, ²Johnson & Johnson Medical Brazil, São Paulo, Brazil, ³Johnson & Johnson Medical, México, D.F., Mexico, ⁴Johnson & Johnson Medical Products, Markham, ON, Canada, ⁵Pharmerit BV, Rotterdam, The Netherlands

17:30-18:30

Research Podiums – Session II

BUDGET IMPACT AND COST STUDIES

B11: COST REDUCTION FOR A HEALTH SYSTEM THROUGH DECREASING NUMBER OF ELIGIBLE PATIENTS FOR BIOLOGICAL THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS USING THE TREAT TO TARGET RECOMMENDATIONS

Santos-Moreno P, Saavedra-Martinez G, Bello-Gualtero J, Gomez-Mora D, Biomab, Centro de Artritis Reumatoide, Bogotá, Colombia

B12: TREATMENT PATTERNS AND BUDGETARY IMPACT OF CHEMOTHERAPY DRUGS IN A BRAZILIAN PRIVATE HEALTH PLAN (PHP)

Nishikawa AM¹, Castro APC¹, Alves AF¹, Medina P¹, Clark LGO², ¹Evidências - Kantar Health, Campinas, Brazil, ²Evidências – Kantar Health, São Paulo, Brazil

B13: FINANCIAL IMPACT OF HOSPITAL EXPENDITURE IN CHRONIC DISEASES FOR SEGURO POPULAR

Rodríguez-Aguilar R, Gutiérrez-Delgado C, Economic Analysis Unit, México, D.F., Mexico

B14: HOSPITALIZATION COSTS OF TYPE-2 DIABETES MELLITUS (T2DM) PATIENTS IN A PUBLIC HOSPITAL IN BRAZIL

Henriques RS¹, Piedade A², Wiens A¹, Baptista DR¹, Pontarolo R¹, ¹Universidade Federal do Paraná, Curitiba, Brazil, ²Evidências - Kantar Health, Campinas, Brazil

CARDIOVASCULAR DISEASE & DIABETES RESEARCH STUDIES

CV1: ASSOCIATION OF ADHERENCE STATUS AS MEASURED USING TWO SINGLE-ITEM PHYSICIAN-ADMINISTERED METHODS WITH CARDIOVASCULAR RISK IN PATIENTS TAKING ANTIHYPERTENSIVE MEDICATION

Rivera O¹, Morales F², Cordova P², Fernandez P², Lopez M², MacDonald K³, Levensgood M⁴, Vancayzele S⁵, Aerts A⁵, Denhaerynck K³, Abraham I⁴, Villa L², ¹Universidad de Concepcion, Concepcion, Chile, ²Facultad de Farmacia, Universidad de Concepcion, Concepcion, Chile, ³Matrix 45, Tucson, AZ, USA, ⁴The University of Arizona, Tucson, AZ, USA, ⁵N.V. Novartis Pharma S.A., Vilvoorde, Belgium

CV2: APIXABAN IN PATIENTS WITH ATRIAL FIBRILLATION: PATIENT CHARACTERISTICS OF THE LATIN AMERICA COHORT FROM A MULTINATIONAL CLINICAL TRIAL

Avezum A¹, Bahit MC², Hermsillo JAG³, Zanetti FL⁴, Perafan P⁵, Juarez-Garcia A⁶, Vulcano C⁷, Cubillos LA⁸, **Korenblat Donato BM⁹**, ¹Dante Pazzanese Institute of Cardiology, São Paulo, Brazil, ²INECO Neurociencias, Rosario, Argentina, ³Instituto Nacional de Cardiología, Mexico, D.F., Mexico, ⁴Universidad de La Frontera, Temuco, Chile, ⁵Fundacion Valle del Lili, Cali, Colombia, ⁶Bristol-Myers Squibb Company, Mexico, D.F., Mexico, ⁷Bristol Myers Squibb, Buenos Aires, Argentina, ⁸Pfizer, New Jersey, NJ, USA, ⁹Bristol Myers Squibb, Wallingford, CT, USA

CV3: ARETAEUS: RETROSPECTIVE STUDY OF MEDICATION USAGE PATTERNS FOLLOWING THE DIAGNOSIS OF TYPE-2 DIABETES IN LATIN AMERICA

Gagliardino JJ¹, Granell RA², Eliaschewitz FG³, Iglay K⁴, Brodovicz K⁴, Yu S⁴, **Gonzalez CD⁴**, Shankar R⁴, Heisel O⁵, Bloomfield S⁵, Keown P⁵, Tunceli K⁴, ¹Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata), Buenos Aires, Argentina, ²Instituto Mexicano del Seguro Social, Guadalajara, Mexico, ³CPclin Clinical Research Center, São Paulo, Brazil, ⁴Merck & Co., Inc., Kenilworth, NJ, USA, ⁵Syreon Corporation, Vancouver, BC, Canada

CV4: ECONOMICS OF DIABETES MELLITUS: THEORY AND EVIDENCE FOR BRAZILIAN DATA IN 2008

Balbinotto G, Wiest R, Jacinto P, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

HEALTH TECHNOLOGY ASSESSMENT STUDIES

HT1: RAPID INCREASE OF HEALTH LITIGATION AS A MEANS OF MARKET ACCESS FOR INNOVATIVE MEDICINES IN COLOMBIA AND THE POTENTIAL ROLE OF HEALTH TECHNOLOGY ASSESSMENT

Leon Kershaw A, Izmirlieva M, IHS, London, UK

HT2: FROM LAW TO REALITY: MEASURING TIME-TO-ACCESS OF CONITEC APPROVED DRUGS IN BRAZILIAN PUBLIC HEALTH CARE SYSTEM (SUS) IN THE STATE OF PARANÁ

Piedade AD¹, Henriques RS², ¹Evidências - Kantar Health, Campinas, Brazil, ²Universidade Federal do Paraná, Curitiba, Brazil

HT3: IS LATIN AMERICA READY FOR THE IMPLEMENTATION OF RISK SHARING AGREEMENTS?

Senan B, Vidal-Pinheiro A, Sandorff E, ICON, London, UK

Session titles are listed in this Program as originally submitted by the Presenter(s) and are subject to change. Confirmed session languages will be available at the ISPOR website – www.ispor.org.



ISPOR 5TH LATIN AMERICA CONFERENCE

6-8 September 2015, Santiago, Chile

Conference Program continued

HT4: PROCESO DE INCORPORACIÓN DE FÁRMACOS A LA LISTA POSITIVA DE MEDICAMENTOS (LPM) PARA LOS PRESTADORES INTEGRALES DE SALUD: EXPERIENCIA EN EL MINISTERIO DE SALUD PÚBLICA (MSP) DE URUGUAY

Croci A, Deminco A, Villamil E, Aleman A, Perez Galan A, Ministry of Public Health, Montevideo, Uruguay

PATIENT AND CLINICIAN PREFERENCES & QALY STUDIES

PP1: BARRIERS TO PARTICIPATION IN TRIALS OF CANCER: A SURVEY ON CLINICAL RESEARCH PERCEPTION

Holtz L¹, Cecilio L¹, Julian G², Minowa E³, ¹Oncoguia, São Paulo, Brazil, ²Evidências - Kantar Health, São Paulo, Brazil, ³Evidências - Kantar Health, Campinas, Brazil

PP2: AN EQ-5D-5L VALUE SET BASED ON URUGUAYAN POPULATION PREFERENCES: REPORT OF THE FIRST EXPERIENCE IN LATIN AMERICA

Augustovski F¹, Rey-Ares L¹, Irazola V¹, Garay U¹, Gianneo O², Fernandez G², Morales MR², Gibbons L¹, Ramos-Goñi JM³, ¹Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, ²Fondo Nacional de Recursos, Montevideo, Uruguay, ³The EuroQol Group Foundation, Rotterdam, The Netherlands

PP3: COST-EFFECTIVENESS ANALYSIS FOR CERVICAL CANCER SCREENING USING HPV TESTS IN BRAZIL

Franco Figueira S¹, **Cachoeira CV**¹, Petry Hasegawa AC², Kano BY¹, Souza FH¹, ¹Roche Diagnostics LATAM, São Paulo, Brazil, ²Roche Diagnostics Brazil, São Paulo, Brazil

PP4: AN UNDEVELOPED PICTURE: THE AVAILABILITY OF UTILITY VALUATIONS IN LATIN AMERICA – HOW WILL THEY AFFECT QALYS?

Montgomery S, Stewart G, Kusel J, Costello Medical Consulting Ltd., Cambridge, UK

RESEARCH ON METHODS STUDIES

RM1: STANDARDIZATION PROCESS OF RAW DATASUS AND CONSUMPTION ANALYSIS OF ONCOLOGY THERAPIES IN THE BRAZIL PUBLIC HEALTH CARE SYSTEM: A COMPARISON BETWEEN RAW AND STANDARDIZED DATASET IN COLORECTAL AND LUNG CANCER

Fabre Ballalái Ferraz A¹, Rosim R¹, Anaya P², ¹IMS Health, São Paulo, Brazil, ²IMS Health, Mexico, D.F., Mexico

RM2: EXTRACTING AND USING DATA FROM ELECTRONIC MEDICAL RECORDS (EMR) TO MONITOR QUALITY OF CARE AND PRESCRIPTION PATTERNS FOR DIABETES PREVENTION AND CONTROL IN OUTPATIENT CLINICS OF LOW AND MID RESOURCES COUNTRIES: THE CASE OF COLIMA, MEXICO

Hernández-Ávila JE¹, Lara A², Morales-Carmona E¹, Espinoza EG², Anaya P³, Palacio-Mejía LS¹, ¹Instituto Nacional de Salud Pública, Cuernavaca, México, ²Secretaría de Salud de Colima, Colima, Mexico, ³IMS Health, México, D.F., Mexico

RM3: COMPARISON OF SOCIAL EQ-5D TIME TRADE-OFF VALUES IN CHILE 2008-2013: DO GEOGRAPHICAL DIFFERENCES REALLY MATTER?

Zárate V¹, Kind P², Valenzuela P³, ¹Ministerio de Salud, Santiago, Chile, ²University of Leeds, Leeds, United Kingdom, ³Datavoz, Santiago, Chile

RM4: MODELO DE CARACTERIZACIÓN DE UNA POBLACIÓN AFILIADA A UNA ASegurada EN COLOMBIA, MEDIANTE UNA METODOLOGÍA DE AGRUPACIÓN POR RIESGO

Romero M¹, Benavides M¹, Alzate P¹, Reinales J², Quinche G², Barrios E², ¹Salutia Foundation, Bogotá, Colombia, ²Cooemeva Group, Cali, Colombia

18:30-19:30

Research Poster Author Discussion Hour – Session I

18:30-20:00

Research Posters & Exhibitors' Reception & Research Poster Presentations Viewing – Session I

19:30-20:30

Educational Symposium

HIGH COST MEDICINES AND HEALTH CARE REFORM – DEVELOPING SUSTAINABLE ACCESS TO MEDICINES IN LATIN AMERICA

This symposium will provide an update and critical assessment of health care reforms and how they are impacting access to health care in the region, as well as outline innovative mechanisms and policies that can provide a sustainable framework to improve patient access to medicines in Latin America. (Sponsored by Teva Pharm)

Tuesday, 8 September

8:30-15:00

Research Poster Presentations Viewing – Session II

9:00-10:30

Second Plenary Session

ACCESS TO HIGH COST DRUGS IN LATIN AMERICA: WHO GOES FIRST?

Health systems in Latin America are currently experiencing constant pressure from patient groups, many of which are supported by the manufacturers themselves, as they seek access to high cost drugs via the prosecution of claims in the court system. The end goal of these claims is to ensure the financing of high cost medicines. In response to this trend, and given the natural complexity of pharmacological therapies, countries are now developing strategies to finance access to high cost drugs. Given the scarcity of available resources, it is necessary to prioritize their allocation. This session aims to review such activities in the region, and inquire about some of the critical aspects of prioritization, namely: Have certain health problems been favored and why? What types of drug therapies have high priority? Who makes these assignments? What criteria are used in the prioritization process? Are certain patient groups privileged and why? Are these solutions long or short term answers? In short, who comes first and who must wait for access to expensive drugs?

10:30-11:00

Break, Exhibits & Research Poster Presentations Viewing – Session II

11:00-12:00

Issue Panels – Session II

IP6: MULTI-CRITERIA DECISION ANALYSIS FOR RARE DISEASES: IS IT FEASIBLE TO BE UTILIZED FOR ALL DISEASES?

Moderator: Vladimir Zah, ZRx Outcomes Research Inc., Belgrade, Serbia and Montenegro
Panelists: Cristina Nunes Ferreira, MSc, MBA, Pfizer Inc., São Paulo, Brazil; **Carl Asche, PhD, MSc**, University of Illinois, Peoria, IL, USA; **Otavio Clark, PhD, MSc**, Evidências-A Kantar Health Company, Rio de Janeiro, Brazil

IP7: DIFERENCIA DE LAS EVALUACIONES DE DISPOSITIVOS MÉDICOS Y FÁRMACOS: ¿CUÁLES SON LAS IMPLICACIONES EN LA TOMA DE DECISIONES?

Moderator: Veronica Gallegos, MSc, Centro Nacional de Excelencia Tecnológica en Salud (CENETEC), México, D.F., Mexico

Panelists: Rosa María Galindo-Suárez, MHE, General Health Council, México, D.F., Mexico; **John J Orozco, MD**, Medtronic, Medellín, Colombia; **Olivo Omar Zanela, MSc, MF**, Johnson & Johnson Medical Mexico, México, D.F., Mexico

IP8: FONDOS ESPECIALES PARA EL FINANCIAMIENTO DE DROGAS DE ALTO COSTO: ¿CUÁLES SON LAS EXPERIENCIAS DE LATINOAMERICA?

Moderator: Nicolás Silva-Illanes Silva, MD, MPP, MPH, University of Chile, Santiago, Chile

Panelists: Alarico Rodríguez, MD, Fondo Nacional de Recursos para la Medicina Altamente Especializada, Montevideo, Uruguay; **Rony Lenz, MSc**, University of Chile, Santiago, Chile; **Lizbeth Acuña, Magister**, Cuenta de Alto Costo, Bogotá, Colombia



ISPOR 5TH LATIN AMERICA CONFERENCE

6-8 September 2015, Santiago, Chile

Conference Program continued

IP9: HOW TO USE CLINICAL TRIALS TO IMPROVE EFFICIENCY OF HEALTH CARE SYSTEMS IN LATIN AMERICA?

Moderator: Pedro Saramago Goncalves, MSc, PhD, University of York, Heslington, York, UK

Panelists: Manuel Espinoza Sepúlveda, MD, MSc, PhD, Pontificia Universidad Católica de Chile, Santiago de Chile, Chile; Federico Augustovski, MD, MSc, PhD, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina; Belén Corbacho, MSc, University of York, Heslington, York, UK

IP10: VALUE-BASED PRICING FOR PHARMACEUTICALS: WHAT ARE THE IMPLICATIONS FOR LATIN AMERICA?

Moderator: Heidy Cáceres Rubio, MD, MHE, Amgen Colombia, Bogotá, Colombia

Panelists: J. Jaime Caro, MDCM, FRCPC, FACP, Evidera, Lexington, MA, USA; Virginia Becerra, MSc PhD, AbbVie, Montevideo, Uruguay; Sean D. Sullivan, PhD, University of Washington, Seattle, WA, USA

12:00-13:00

Research Poster Author Discussion Hour – Session II

12:00-15:00

Lunch, Exhibits & Research Poster Presentations Viewing – Session II

15:00-16:00

Workshops & ISPOR Forum – Session II

W6: WILLINGNESS-TO-PAY VERSUS WILLINGNESS-TO-HATE: THE ISSUE OF COST-EFFECTIVENESS IN ONCOLOGY

Discussion Leaders: Diego Rosselli, MD, EdM, MSc, Pontificia Universidad Javeriana, Facultad de Medicina, Bogotá, Colombia; Stephen Stefani, MD, UNIMED, Porto Alegre, Brazil; Alexancer Itria, Goiania University, Goiás, Brazil; Diana Tellez, MD, MPH, Janssen Cilag S.A, Bogotá, Colombia

W7: EQUITY CONSIDERATIONS IN HEALTH CARE DECISION MAKING: WHAT DOES IT MEAN AND HOW IS IT MEASURED?

Discussion Leaders: Sebastián García Martí, ManH, MD, MSc, IECS, Buenos Aires, Argentina; Manuel A. Espinoza, MD, MSc, PhD, Pontificia Universidad Católica de Chile, Santiago, Chile; Báltica Cabieses, MSc, PhD, Universidad del Desarrollo, Santiago, Chile

W8: CÓMO GESTIONAR LOS MEDICAMENTOS DE ALTO IMPACTO FINANCIERO MEDIANTE EL TRABAJO COLABORATIVO DE EVALUACIONES DE TECNOLOGÍA SANITARIA ENTRE LOS PAÍSES DE AMÉRICA LATINA Y EL CARIBE

Discussion Leaders: Ana Lucía Muñoz Mejía, Esp., Banco Interamericano de Desarrollo, Bogotá, Colombia; Rosa María Galindo-Suárez, MHE, General Health Council, México, D.F., Mexico; Xavier Sánchez, MD, Esp., Ministerio de Salud Pública, Quito, Ecuador; Hernando Gaitán Duarte, MD, MSc, Universidad Nacional de Colombia, Bogotá, Colombia

W9: HURDLES AND BEST PRACTICES IN THE USE OF REAL-WORLD EVIDENCE IN ARGENTINA, BRAZIL, AND MEXICO: FROM REGISTRATION TO DISSEMINATION

Discussion Leaders: Nahila Justo, MPhil, MSc, MBA, MAPI Group, Stockholm, Sweden; Gabriel E. Novick, MD, PhD, Swiss Medical Group, Buenos Aires, Argentina; Luis Ángel Vázquez Martínez, Lic., Secretaría de Salud del Distrito Federal, México, D.F., Mexico; Antonio Carlos Endrigo, MD, Centro de Inovação e Tecnologia (CITEC-USP), São Paulo, Brazil

W10: ECONOMIC IMPACT OF OBESITY: METHODOLOGICAL CHALLENGES FOR THE LATIN AMERICAN REGION

Discussion Leaders: Cristóbal Cuadrado, MD, MPH, Universidad de Chile, Santiago, Chile; Simón Barquera, MD, MS, PhD, Instituto Nacional de Salud Pública, Cuernavaca, Mexico; Rodrigo Martínez, MA, United Nations Economic Commission for Latin America and the Caribbean (ECLAC), Santiago, Chile; Oscar C. Vásquez, MS, PhD, Universidad de Santiago de Chile, Santiago, Chile

F2: VALUE IN HEALTH REGIONAL ISSUES (VIHRI) IN LATIN AMERICA: FROM QUALITY RESEARCH TO PUBLICATION SUCCESS

Presented by Value in Health Regional Issues (VIHRI)

Moderator: Federico Augustovski, MD, MSc, PhD, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina

Speakers: J. Jaime Caro, MDCM, FRCPC, FACP, Evidera, Lexington, MA, USA; Víctor Zárate, MD, Ministerio de Salud, Santiago, Chile; Marcos Bosi Ferraz, MD, MSc, PhD, Federal University of São Paulo (UNIFESP) and São Paulo Center for Health Economics (GRIDES), São Paulo, Brazil

16:00-16:15

Break & Exhibits Viewing

16:15-17:15

Workshops & ISPOR Forum – Session III

W11: ANÁLISIS DE DECISIONES MULTICRITERIO: ¿ES LA MEJOR MANERA DE CONDUCIR LAS DECISIONES SOBRE COBERTURA EN SALUD EN LATINOAMÉRICA?

Discussion Leaders: Adriana Ávila, BSc, Instituto de Evaluación Tecnológica en Salud (IETS), Bogotá, Colombia; Hector Eduardo Castro Jaramillo, MD, PhD, Instituto de Evaluación Tecnológica en Salud (IETS), Bogotá, Colombia; Manuel A. Espinoza, MD, MSc, PhD, Pontificia Universidad Católica de Chile, Santiago, Chile

W12: DESDE LA EVALUACIÓN DE TECNOLOGÍAS SANITARIAS A LAS GUÍAS DE PRÁCTICA CLÍNICA: EL GRADE APPROACH

Discussion Leaders: Ignacio Neumann, MD, MSc, PhD, Pontificia Universidad Católica de Chile, Santiago, Chile; Francisca Rodríguez, MD, Ministerio de Salud, Santiago, Chile

W13: MODELAMIENTO DE VARIABLES LATENTES EN INVESTIGACIÓN EN SALUD: UNA APROXIMACIÓN AL ANÁLISIS DE ECUACIONES ESTRUCTURALES

Discussion Leaders: Victor Pedrero, MSc, Universidad del Desarrollo, Santiago, Chile; Baltica Cabieses, MSc, PhD, Universidad del Desarrollo, Santiago, Chile; Marcela Oyarte, BSc, Universidad del Desarrollo, Santiago, Chile; Pedro Zitko, MSc, Complejo Asistencial Barros Luco, Santiago, Chile

W14: EXPLORING INNOVATIVE APPROACHES TO CREATE REAL-WORLD EVIDENCE IN LATIN AMERICA

Discussion Leaders: Marília Gomes, MD, Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brazil; Juan Eugenio Hernández Ávila, MSc, DSc, Instituto Nacional de Salud Pública, Cuernavaca, México; Claudia Rodrigues Soares, PhD, GlaxoSmithKline, Rio de Janeiro, Brazil; Joshua Hiller, MBA, IMS Health, London, UK

W15: EQ-5D: THE ABC APPROACH TO MEASURING AND VALUING HEALTH IN LATIN AMERICA

Discussion Leaders: Paul Kind, University of Leeds, Leeds, UK; Víctor Zárate, MD, Ministerio de Salud, Santiago, Chile; Federico Augustovski, MD, MSc, PhD, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina; Kenya Noronha, PhD, Cedeplar-FACE-UFMG, Belo Horizonte, Brazil

F3: UNDERSTANDING GAPS FOR TECHNOLOGY ADOPTION IN THREE SOUTH AMERICAN COUNTRIES

Presented by the ISPOR Argentina Chapter

Moderator: Ramiro Gilardino, MD, MSc, Johnson & Johnson, Buenos Aires, Argentina

Speakers: Andrés Pichon-Riviere, MD, MSc, PhD, Institute of Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina; Rony Lenz, MA, Universidad de Chile, Santiago, Chile

17:30-18:00

ISPOR Research Awards Presentation & Closing Remarks

Session titles are listed in this Program as originally submitted by the Presenter(s) and are subject to change. Confirmed session languages will be available at the ISPOR website – www.ispor.org.



Why Attend ISPOR Santiago?

What Does an ISPOR Latin America Conference Offer?

ISPOR is recognized globally as the leading educational and scientific organization for outcomes research and its use in health care decisions. If you want to meet leaders in the health economics and outcomes research (HEOR) field, discuss the latest trends, and learn from the experts... attend ISPOR Santiago!

The ISPOR Latin America Conference features two thought-provoking Plenary Sessions and more than 450 presentations in the form of workshops, issue panels, forums, symposia, podium, and poster presentations focused on patient access to care, innovative research methods, health policy development using outcomes research, patient preferences, real world data, clinical, economic, and patient-reported outcomes.

In addition, ISPOR offers a full day of pre-conference training courses on trending topics in the HEOR field ranging from the basics in economic methods to patient preference methods and advanced modeling applications. These courses are presented by leading experts in the field from Latin America and abroad and often include hands-on training opportunities. The ISPOR Short Course Program is an intrinsic component to ISPOR's training and education opportunities and should not be missed!

Who Attends?

The ISPOR scope and sphere of influence includes outcomes researchers, health technology developers and assessors, regulators, health economists, health care policy makers, payers, providers, patients, populations, and society as a whole. The diversity in work environments and international scope of attendance provide excellent networking opportunities and stimulating discussions and debate.

Why Attend?

- **Learn** new & novel experiences in the conduct/use of HEOR.
- **Stay current** via cutting edge plenary sessions and presentations on innovative and controversial issues.
- **Share** research, ideas, and developments in the field and help to advance the science.
- **Network** and renew connections with clients, colleagues, or collaborators.

A reflection on the last ISPOR Latin America Conference:

ISPOR 4th Latin America Conference, Buenos Aires, Argentina:

- Over 740 attendees
- 44 countries represented
- Over 400 presentations

"Excellente [sic] organization, the sessions were of high quality. Congratulations."

ISPOR 4th Latin America Conference Attendee [Source: Online Conference Evaluation]

Registration Fees

EARLY REGISTRATION DEADLINE: 23 JULY 2015

PRE-CONFERENCE SHORT COURSES	FEES THRU 21 JULY 2015	FEES AFTER 21 JULY 2015
All Day Short Courses (8:00-17:00)	Regular: \$250 (CLP 160mil) Student: \$150 (CLP 95mil)	Regular: \$350 (CLP 222mil) Student: \$200 (CLP 130mil)
Morning Short Courses (8:00-12:00)	Regular: \$125 (CLP 80mil) Student: \$75 (CLP 48mil)	Regular: \$175 (CLP 111mil) Student: \$100 (CLP 65mil)
Afternoon Short Courses (13:00-17:00)	Regular: \$125 (CLP 80mil) Student: \$75 (CLP 48mil)	Regular: \$175 (CLP 111mil) Student: \$100 (CLP 65mil)
CONFERENCE REGISTRATION	FEES THRU 21 JULY 2015	FEES AFTER 21 JULY 2015
Standard	US \$600 (CLP 380mil)	US \$700 (CLP 444mil)
Clinical Practitioners (Clinical Practice, Hospital)	US \$275 (CLP 174mil)	US \$375 (CLP 238mil)
Full-Time Government and Academia	US \$275 (CLP 174mil)	US \$375 (CLP 238mil)
Full-Time Students (must provide current enrollment docs)	US \$100 (CLP 65mil)	US \$150 (CLP 95mil)

NOTE: Exchange rate as of January 2015 (US \$1 = CLP 634)

Register online @ www.ispor.org

Conference Sponsorship & Promotional Opportunities

CORPORATE SPONSORS

ISPOR provides opportunities for organizations to financially support the ISPOR 5th Latin America Conference through educational grants called Corporate Sponsorships. Corporate sponsors receive complimentary conference registration(s) in addition to the benefits listed below. For further information, please email: laconsortium@ispor.org.

Benefits to Corporate Sponsors:

- Recognition at the Plenary Sessions
- Recognition in the Program & Schedule of Events and on the ISPOR website
- Conference signage

EVENT SPONSORS

Increase your visibility! Give your company increased prominence. For information, please email: eventsponsor@ispor.org.

Benefits to all Event Sponsors:

- Recognition at the Plenary Sessions
- Recognition in the Program & Schedule of Events and on the ISPOR website
- Conference signage

Additional Benefits based on level of sponsorship:

- Listing and ¼ page advertisement in the Program & Schedule of Events
- Listing and ¼ page advertisement on the ISPOR website

EXHIBIT

Register now for exhibit space!

Present your products and services to key outcomes researchers and health care decision makers in pharmaceutical, medical device and diagnostics, biotechnology industries, clinical practice, government agencies, academia, and health care organizations.

Benefits to Exhibitors:

- Listing and ¼ page advertisement in the Program & Schedule of Events
- Listing and ¼ page advertisement on the ISPOR website
- Complimentary conference registration
- Pre-registrant mailing labels

ADVERTISE!

Advertise in the Program & Schedule of Events! Advertising Deadline: 3 July 2015